ArticleJournal of neurology2025
Diagnostic utility of tectal plate measures in clinical variants of progressive supranuclear palsy.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe length of the tectal plate, which sits above the midbrain, is reduced in both the Richardson's syndrome (RS) and parkinsonism (P) variants of progressive supranuclear palsy (PSP). However, it is unclear whether tectal measurements could be useful biomarkers in other PSP variants or predict PSP pathology.
methodsThe Neurodegenerative Research Group, Mayo Clinic, enrolled 115 PSP (including seven variants), 19 corticobasal syndrome (CBS), 21 Parkinson's disease (PD), and 50 controls. Forty-seven PSP patients had PSP at autopsy, and 15 had a non-PSP pathology. Tectal plate length and area and area of the superior/inferior colliculi were measured. Measurements were compared across clinical and pathological groups, and associations were assessed with clinical severity. Effect sizes were evaluated using the area under the receiver operator characteristic curves (AUROCs).
resultsAll PSP variants showed reduced tectal plate length compared to controls, with good differentiation (AUROC > 0.80). Excellent differentiation was observed for PSP-RS and PSP-P from controls (AUROC = 0.93/0.86), and PD (AUROC = 0.92/0.83), and PSP-RS showed good differentiation from CBS (AUROC = 0.80). Tectal plate and superior colliculus areas were reduced in all PSP variants, except PSP-Speech-language (SL), compared to controls. PSP-RS and PSP-P showed reduced area measurements compared to PSP-SL. No differences were observed between PSP and non-PSP pathology. Reduced tectal plate length was associated with worse clinical severity in PSP.
conclusionTectal plate length may have utility as a disease biomarker across PSP variants, although tectal plate measurements could not predict pathology within patients clinically diagnosed with PSP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.